Literature DB >> 8670148

Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase.

J M Lenhard1, D B Kassel, W J Rocque, L Hamacher, W D Holmes, I Patel, C Hoffman, M Luther.   

Abstract

A cAMP-specific phosphodiesterase, HSPDE4B2B, was found to be phosphorylated when expressed in Sf9 cells or yeast. Deletion of amino acids 81-151 and 529-564 had no effect on the phosphorylation of HSPDE4B2B. Mass spectrometric analysis of purified HSPDE4B2B(1-564). HSPDE4B2B(81-564) and HSPDE4B2B(152-528) showed that phosphorylation occurred predominantly on Ser487 and Ser489. The stoicheiometry of phosphorylation was 1.2:1 (Ser487:Ser487, 489). There was no evidence by MS for a non-phosphorylated form of HSPDE4B2B(81-564) or HSPDE4B2B(152-528) when expressed in Sf9 cells. There was no detectable phosphorylation of purified HSPDE4B2B(152-528) expressed in Escherichia coli. Radiolabelling experiments with 32P revealed that phosphorylation of HSPDE4B2B(152-528) expressed in Sf9 cells was abolished when Ser487 and Ser489 were mutated to alanines. Analysis of the amino acid sequence revealed that Ser487 and Ser489 of HSPDE4B2B conform to the consensus motifs for phosphorylation by mitogen-activated protein kinase (MAP kinase) and casein kinase II respectively. Kinetic experiments in vitro showed that MAP kinase-phosphorylated E.coli expressed and purified HSPDE4B2B(151-528) with a K(m) of 63 microM and a Vmax of 3.0 mumol/min per mg. In comparison, MAP kinase phosphorylated myelin basic protein with a Km of 26.0 microM and a Vmax of 5.5 mumol/min per mg under the same conditions. Using MS and mutational analysis we found that MAP kinase-phosphorylated E. coli expressed HSPDE4B2B(152-528) exclusively at Ser487. These results suggest that phosphodiesterases could contribute to the cross-talk between the cAMP and MAP kinase signalling pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670148      PMCID: PMC1217414          DOI: 10.1042/bj3160751

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

1.  Purification and characterization of a maturation-activated myelin basic protein kinase from sea star oocytes.

Authors:  J S Sanghera; H B Paddon; S A Bader; S L Pelech
Journal:  J Biol Chem       Date:  1990-01-05       Impact factor: 5.157

Review 2.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Insulin stimulates the tyrosyl phosphorylation and activation of the 52 kDa peripheral plasma-membrane cyclic AMP phosphodiesterase in intact hepatocytes.

Authors:  N J Pyne; W Cushley; H G Nimmo; M D Houslay
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

6.  Cloning and characterization of mammalian homologs of the Drosophila dunce+ gene.

Authors:  R L Davis; H Takayasu; M Eberwine; J Myres
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

7.  Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase.

Authors:  J Colicelli; C Birchmeier; T Michaeli; K O'Neill; M Riggs; M Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Polymer support oligonucleotide synthesis XVIII: use of beta-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product.

Authors:  N D Sinha; J Biernat; J McManus; H Köster
Journal:  Nucleic Acids Res       Date:  1984-06-11       Impact factor: 16.971

9.  Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.

Authors:  M W Verghese; R T McConnell; J M Lenhard; L Hamacher; S L Jin
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

10.  Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.

Authors:  H Wachtel
Journal:  Neuropharmacology       Date:  1983-03       Impact factor: 5.250

View more
  5 in total

1.  Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases.

Authors:  G S Baillie; S J MacKenzie; I McPhee; M D Houslay
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

2.  The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.

Authors:  R Hoffmann; G S Baillie; S J MacKenzie; S J Yarwood; M D Houslay
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

3.  Computational investigation of the dynamic control of cAMP signaling by PDE4 isoform types.

Authors:  Dean Paes; Sammy Hermans; Daniel van den Hove; Tim Vanmierlo; Jos Prickaerts; Aurélie Carlier
Journal:  Biophys J       Date:  2022-06-18       Impact factor: 3.699

Review 4.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.